Precision BioSciences, Inc.
NASDAQ:DTILBiotechnology
+$0.11 today
- Market cap
- $193.04M
- Beta
- 1.28
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$3.47
Volume 0.27M
Average 0.31M
Income Statement
Follow revenue through to earnings.
Revenue
$34.26M
FY 2025 · Annual
-50.1% YoYOperating Income
-$52.15M
FY 2025 · Annual
Net Income
-$46.61M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 115.53M | 25.1M | 48.73M | 68.7M | 34.26M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.75M |
| Gross Profit | 115.53M | 25.1M | 48.73M | 68.7M | 31.51M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 92.0% |
| Research & Development | 115.24M | 46.12M | 53.38M | 59.56M | 54.17M |
| Selling, General & Admin | 39.67M | 41.28M | 39.09M | 35.3M | 32.24M |
| Operating Expenses | 154.91M | 87.41M | 92.46M | 94.86M | 83.66M |
| Depreciation & Amortization | 10.2M | 9M | 8.26M | 4.58M | 2.75M |
| EBITDA | (20.27M) | (62.79M) | (32.04M) | 13.53M | (42.43M) |
| EBITDA Margin | -17.5% | -250.2% | -65.8% | 19.7% | -123.8% |
| Operating Income | (39.38M) | (62.31M) | (43.74M) | (26.16M) | (52.15M) |
| Operating Margin | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% |
| Interest Income | 208K | 3.47M | 7.69M | 6.76M | 4.24M |
| Interest Expense | 132K | 1.11M | 2.23M | 1.78M | 1.42M |
| Other Income / Expenses | 8.77M | (10.6M) | 1.21M | 33.33M | 5.54M |
| Income Before Tax | (30.6M) | (72.91M) | (42.53M) | 7.17M | (46.61M) |
| Pre-Tax Margin | -26.5% | -290.5% | -87.3% | 10.4% | -136.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.6M) | (111.64M) | (61.32M) | 7.17M | (46.61M) |
| Net Margin | -26.5% | -444.8% | -125.8% | 10.4% | -136.0% |
| EPS (Basic) | (15.60) | (38.10) | (15.96) | 1.05 | (3.63) |
| EPS (Diluted) | (15.60) | (38.10) | (15.96) | 1.04 | (3.63) |
| 1.96M | 2.93M | 3.84M | 6.83M | 12.83M | |
| 1.96M | 2.93M | 3.84M | 6.88M | 12.83M |
DTIL Earnings Waterfall · TTM
NASDAQ:DTIL · Revenue to Net Income
Key Ratios
Analysis
$45.1M of revenue converted into -$44.5M of net income for the selected period. Gross margin is -867.2% and net margin is -74564.4%, showing how much revenue survives after costs and taxes. EPS is $-4.41, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 424B5 | 424B5 filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| FWP | FWP filing | Nov 5, 2026 |
How much revenue does DTIL generate?
Precision BioSciences, Inc. (DTIL) reported $34.26M of revenue in fiscal 2025.
Is DTIL profitable?
Precision BioSciences, Inc. (DTIL) reported -$46.61M of net income, with a net margin of -136.0%.
Continue the stock analysis
Jump to another research area for this company.